Trial NCT04730349

View at ClinicalTrials.gov 
Org. Study IDs: CA045-020
Secondary IDs: 2020-000854-85

Last trial update was posted on 2023-03-24

MeSH Interventions

Nivolumab

MeSH Conditions

Brain Neoplasms Ependymoma Glioma Leukemia Lymphoma Medulloblastoma Neuroblastoma Rhabdomyosarcoma Sarcoma Sarcoma, Ewing

Other Conditions

Ewing Sarcoma High-grade Glioma Leukemia and Lymphoma Miscellaneous Brain Tumors Miscellaneous Solid Tumors Relapsed, Refractory Malignant Neoplasms

Stopping Reasons

Business objectives have changed

Limitations And Caveats

On 14-Apr-2022, a joint decision was made to end the clinical development program for bempegaldesleukin in combination with nivolumab, resulting in the termination of this study. This results disclosure report provides analyses from CA045-020 Part A safety analyses only. Part B of the study (expansion phase) did not enroll any participants.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID